Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides

• US 4,522,811 A
• Filed: 07/08/1982
• Issued: 06/11/1985
• Est. Priority Date: 07/08/1982
• Status: Expired due to Fees

• Current Assignee: Syntec Incorporated (Atos SE)
• Original Assignee: Syntec Incorporated (Atos SE)
• Inventors: Eppstein, Deborah A., Matthews, Thomas R., Fraser-Smith, Elizabeth B.
• Primary Examiner(s): Phillips, Delbert R.
• Assistant Examiner(s): Moezie, F. T.
• Application Number:
  US06/396,213
• Time in Patent Office: 1,069 Days
• Field of Search: 424/177, 260/112.5 R
• US Class Current: 514/2.4
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 38/14 Peptides containing saccharide radicals; Derivatives thereof , e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• CPC Class Codes: A61K 9/127 Liposomes

Abstract

Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.

Claims

1. A method for enhancing the anti-infective activity of a muramyldipeptide (MDP) compound which method comprises serial intravenous injection to an animal in need thereof an anti-infective enhancing amount of unencapsulated MDP compound and liposomes within three hours of each other wherein said MDP compound.

2. The method of claim 1 wherein said liposomes and MDP compound are injected within two hours of each other.

3. The method of claim 1 wherein said MDP compound is N-acetyldesmethylmuramyl-L-alanyl-D-isoglutamine.

4. The method of claim 1 wherein the MDP compound is N-acetylmuramyl-L-alanyl-D-isoglutamine.

5. The method of claim 1 wherein the MDP compound is N-acetyldesmethylmuramyl-L-alpha-aminobutyryl-D-isoglutamine.

6. The method of claim 1 wherein said MDP compound is N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine.

7. The method of claim 1 wherein said MDP compound is N-acetylmuramyl-L-valyl-D-isoglutamine.

8. The method of claim 1 wherein said MDP compound is N-acetylmuramyl-L-threonyl-D-isoglutamine.

9. The method of claim 1 wherein said MDP compound is N-acetylmuramyl-L-seryl-D-isoglutamine.